Numinus becomes the first publicly traded company in Canada to obtain such licensing for psychedelics research.
Exploring the companies and themes that make up this emerging and exciting new sector
Will Compass Pathways Be The Next Unicorn?
As rumors swirl about Compass Pathways going public, this could become the first psychedelics Unicorn.
MindMed Begins Phase 2 Clinical Trial of LSD for Treating "Suicide Headaches"
MindMed begins a Phase 2 clinical trial of LSD for cluster headaches in Switzerland.
Dr. Devon Christie, MD CCFP RTC IFMCP, joins Numinus as Medical Director
Numinus adds to its management team.
MindMed Further Expands Phase 2 Clinical Trial of Microdosing LSD For Adult ADHD
MindMed's Microdosing Division is expanding its ADHD clinical trial.
Champignon Announces Voluntary Share Lock-Up; Retains Gold Standard Media, LLC for Financial Marketing
Certain shareholders have agreed to a voluntary resale restriction that covers 17.8 million shares.
Numinus Announces 2020 Operational Plans to Scale
Newly-listed Numinus Wellness provides a corporate update.
Psychedelic Drug Therapy: Laying Out The Picture
Psychedelic drug proponents have touted some very exciting clinical studies. Investors will want to look past the headlines and take a closer look at these drug therapies.
MindMed Adds MDMA for Development of Next-Gen Psychedelic Therapies
MindMed further expands R&D collaboration with University Hospital Basel's Liechti Lab with plans to develop next-gen psychedelic therapies combining LSD and MDMA.
MindMed Closes on Upsized Financing of $13.2m
MindMed has issued 24.95 million units at a unit price of CAD$0.53.
Dr. Gabor Maté joins Numinus as Member of the Clinical Advisory Council
Maté will collaborate with the Numinus team in an advisory capacity and facilitate connections within the mental health community.
Champignon Appoints Dr. Bill Wilkerson to Board of Directors
Champignon Brands' new Director has extensive mental health credentials.